MktsMarkets

REGENXBIO Inc.
NASDAQ: RGNXKey statistics
RGNX News
Stories mentioning RGNX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6,393 | 30,337 | 29,733 | 21,359 | 89,012 | 21,214 | 24,197 | 22,295 |
| Cost of Goods Sold | 6,318 | 12,387 | 10,579 | |||||
| Gross Profit | 14,896 | 11,810 | 11,716 | |||||
| Operating Expenses | ||||||||
| Research & Development | 57,339 | 59,611 | 56,101 | 59,500 | 53,087 | 50,380 | 54,429 | 48,869 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (83,362) | (57,636) | (52,411) | (63,278) | 12,127 | (51,368) | (62,078) | (56,037) |
| Interest Income | 2,000 | 2,700 | 3,600 | 3,400 | 2,500 | 2,800 | 3,300 | 3,500 |
| Interest Expense | 449.00 | |||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (90,051) | (67,149) | (61,941) | (70,871) | 6,083 | (51,186) | (59,597) | (52,989) |
| Earnings Per Share (Basic) | (1.72) | (1.30) | (1.20) | (1.38) | 0.12 | (1.03) | (1.17) | (1.05) |
| Earnings Per Share (Diluted) | (1.72) | (1.30) | (1.20) | (1.38) | 0.12 | (1.03) | (1.17) | (1.05) |
| Weighted Average Shares Outstanding (Basic) | 52,428 | 51,573 | 51,689 | 51,483 | 51,362 | 49,509 | 50,800 | 50,601 |
| Weighted Average Shares Outstanding (Diluted) | 52,428 | 51,573 | 51,689 | 51,483 | 51,434 | 49,509 | 50,800 | 50,601 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RGNX
REGENXBIO Inc. (NASDAQ: RGNX) is a stock listed on the Nasdaq Stock Market under the ticker symbol RGNX. It last traded at $8.07 (Nov 9, 2026, 4:00 PM ET), up 5.9% on the day. That gives REGENXBIO a market capitalisation of $527.0M.
Over the past 52 weeks RGNX has traded between $5.46 and $16.19.
Revenue for the quarter ended Mar 31, 2026 was $6.4M; a net loss of $90.1M. Revenue was down 92.8% from $89.0M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $6.4M | -$90.1M | -1408.6% |
| Dec 31, 2025 | $30.3M | -$67.1M | -221.3% |
| Sep 30, 2025 | $29.7M | -$61.9M | -208.3% |
| Jun 30, 2025 | $21.4M | -$70.9M | -331.8% |
From REGENXBIO’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…